BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give BioNTech a “Moderate Buy” consensus: 13 of 19 analysts rate the stock a buy, four recommend holding, one rates it a sell and one a strong buy. The average 12-month price target is $127.81.
• Recent analyst actions were mixed, with UBS upgrading BioNTech to “buy” and raising its target to $135, while Wells Fargo, Berenberg and Morgan Stanley lowered their price targets.
• BioNTech opened at $92.12 and has traded between $79.52 and $124.00 over the past year. The company also authorized a $1 billion share-repurchase program, covering up to 4.2% of outstanding shares.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $127.8125.

Several research firms have issued reports on BNTX. UBS Group raised BioNTech from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Wall Street Zen cut BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Wells Fargo & Company lowered their price objective on BioNTech from $150.00 to $140.00 and set an "overweight" rating for the company in a research report on Wednesday, May 6th. Berenberg Bank dropped their price objective on BioNTech from $155.00 to $140.00 and set a "buy" rating for the company in a report on Tuesday, May 12th. Finally, Morgan Stanley cut their target price on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 8th.

Institutional Trading of BioNTech

A number of institutional investors have recently bought and sold shares of BNTX. Larson Financial Group LLC lifted its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after purchasing an additional 127 shares during the period. EFG International AG bought a new position in shares of BioNTech in the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock worth $30,000 after purchasing an additional 260 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after purchasing an additional 305 shares during the period. Finally, Vestcor Inc bought a new stake in BioNTech in the fourth quarter valued at about $153,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

BNTX opened at $92.12 on Friday. BioNTech has a one year low of $79.52 and a one year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The company's 50 day simple moving average is $91.59 and its 200-day simple moving average is $96.22. The stock has a market capitalization of $23.30 billion, a P/E ratio of -11.77 and a beta of 1.27.

BioNTech declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source